Randomized controlled trialHumanClinical Trial, Phase III

Bremelanotide for the Treatment of Hypoactive Sexual Desire Disorder: Two Randomized Phase 3 Trials

Obstetrics and gynecology, 2019 Nov. Kingsberg SA, Clayton AH, Portman D and 5 others.

Study type

Randomized controlled trial · Clinical Trial, Phase III

Subjects

Human participants (PubMed MeSH: Humans)

Journal

Obstetrics and gynecology

Published

2019 Nov

PubMed

PMID 31599840 ↗

DOI

10.1097/AOG.0000000000003500 ↗

Full text

Free on PubMed Central (PMC6819021) ↗

Where PepCue cites this

This paper is part of the evidence base behind this profile. Citing a study is not an endorsement of the compound: papers that found no effect are indexed the same way.

PT-141 →pt 141 vs melanotan 2 →

Indexed under

MeSH terms assigned by the National Library of Medicine.

AdultCentral Nervous System AgentsDouble-Blind MethodFemaleHumansInjections, SubcutaneousLibidoPeptides, CyclicPremenopausePsychological DistressReceptor, Melanocortin, Type 3Receptor, Melanocortin, Type 4

Other papers on PT-141

Systematic review / meta-analysis · 2021

Re-Analyzing Phase III Bremelanotide Trials for "Hypoactive Sexual Desire Disorder" in Women

Journal article · 2019

Long-Term Safety and Efficacy of Bremelanotide for Hypoactive Sexual Desire Disorder

PepCue indexes citation metadata only and does not reproduce abstracts or full text. Read the paper at the source links above. Nothing here is medical advice or a dose recommendation.

Educational and research reference only. Not medical advice, diagnosis, or dosing guidance. Flag an error on this page